Merck Plans To Shed 13% Of Work Force By 2015
This article was originally published in The Pink Sheet Daily
The pharma responds to a tough market environment by stepping up its previously-announced cost savings program to total $4 billion to $4.6 billion a year by 2015.
You may also be interested in...
Merck’s new head of worldwide licensing and knowledge management Roger Pomerantz, MD, talks with IN VIVO about Merck’s business development strategy, whether biotech passion can exist on a Big Pharma scale, and the art of the deal.
Incivek, launched in May, already has posted sales of $74.5 million, while Merck's competing Victrelis has tallied $21 million in sales so far.
The Big Pharma reports better than expected first quarter revenues and discusses what is coming in R&D and the cardiovascular pipeline.